MyoStrain® plays a critical role in clinical decision-making during the cancer process, particularly in patients at risk of heart failure. Presented at the Virtual Cardio-Oncology Summit on October 1st, 2020, leading cardio-oncology experts discuss how MyoStrain may help to stratify cardiotoxicity risk, optimize cardiovascular therapy, prevent and manage cardiotoxicity, and guide long-term survivors’ follow-up.
Sponsored by Myocardial Solutions, Inc., the Satellite Symposium program addresses the medical community's most frequently asked questions surrounding the use of MyoStrain® for protecting cancer patient heart health, providing practical, case-based examples to demonstrate the potential of MyoStrain® to significantly improve transform cardio-oncology care.
0:00 - Cardiac Magnetic Resonance in Cardio-Oncology: The Role of Myocardial Strain (Introduction)
Dr. Teresa López-Férnandez
Co-Chair, Virtual Cardio-Oncology Summit 2020; Director, Cardiac Imaging, Cardio-Oncology
Hospital Universitario La Paz, Madrid
5:27 - Cardiac MRI in Cardio-Oncology: Strain at its Best Fidelity
Dr. Daniel J. Lenihan
Co-Chair, Virtual Cardio-Oncology Summit 2020; Professor, Division of Cardiovascular Medicine;
Director, Cardio-Oncology Center of Excellence
Washington University School of Medicine at St. Louis
20:39 - Cardiac MRI in Cardio-Oncology: The Oncology Perspective
Dr. Susan Dent
Co-Chair, Virtual Cardio-Oncology Summit 2020; Medical Oncologist, Duke Cancer Institute;
Co-Director, Duke Cardio-Oncology Program
Duke Cancer Institute
32:58 - Cardiac Magnetic Resonance in Cardio-Oncology: The Role of Myocardial Strain (Closing Remarks)
Dr. Alexander Lyon
Clinical Lead in Cardio-Oncology,
President of British Cardio-Oncology Society,
ESC Cardio-Oncology Council Chair-elect
Royal Brompton Hospital, Imperial College London
41:53 - How MyoStrain® Quantifies Segmental Myocardial Strain
Dr. Nael Osman
Founder & Chief Science Officer
Myocardial Solutions, Inc.
